Kyntra Bio, Inc. (KYNB)
US — Healthcare Sector
Automate Your Wheel Strategy on KYNB
With Tiblio's Option Bot, you can configure your own wheel strategy including KYNB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
KYNB
Published: April 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Published: April 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Kyntra Bio, Inc. (KYNB)
- IPO Date 2014-11-14
- Website https://www.kyntrabio.com
- Industry Medical - Pharmaceuticals
- CEO Thane Wettig
- Employees 225
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.